Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naive Adults With Early Active Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms C-EARLY
- Sponsors UCB Pharma SA
- 02 Nov 2016 Analysis of clinical responses and workplace/household productivity improvements in patient-reported outcomes (n=655) were presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 10 May 2016 Results published in the Annals of the Rheumatic Diseases
- 10 May 2016 Primary endpoint (Percentage of subjects with Disease Activity Score) has been met as results published in the Annals of the Rheumatic Diseases